If you’re comparing Mounjaro and Wegovy, you’re usually trying to answer one practical question:

“Which one makes more sense for me in the UK based on eligibility, dosing, and real-world use?”

This guide focuses on differences that change decisions, not generic marketing claims. If you’re starting Mounjaro through MedCare, your next step remains the clinician-reviewed consultation on Mounjaro weight loss injection pen.

Table of Contents

1) Active ingredient (the real “what is it” difference)

Mounjaro = tirzepatide

The MHRA describes Mounjaro for weight management as a pre-filled injection pen containing tirzepatide in multiple strengths.

Tirzepatide is commonly explained as a dual GIP + GLP-1 receptor agonist (we explained the mechanism clearly in How Mounjaro Works for Weight Loss).

Wegovy = semaglutide

Wegovy’s patient leaflet shows dose escalation for semaglutide used for weight management, increasing gradually up to a maintenance dose, and now includes an approved higher maintenance option in some patients.

Why this matters: different active ingredients = different dosing systems, escalation steps, and sometimes different clinical preferences based on your history.

2) Dosing & pen reality (what you actually inject)

Mounjaro strengths (UK)

The MHRA states Mounjaro is available for weight management as a pre-filled pen with 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg strengths.

Wegovy dosing (UK) + January 2026 update

Wegovy’s patient leaflet describes a gradual dose increase every 4 weeks up to 2.4mg once weekly. It also states that if needed, a dose increase to 7.2mg once weekly can be made after at least 4 weeks on 2.4mg, and that 7.2mg is delivered as 3 injections of 2.4mg on the same day.

UK update (important): The MHRA announced approval of the 7.2mg Wegovy weight management dose (injections).

Why this matters:

If you hate the idea of multiple injections on the same day, that’s a practical preference factor.
Dose escalation and tolerability are real-life issues; titration exists to manage side effects, not to “delay results.”

3) NICE eligibility (NHS pathway) they’re not identical

NICE for tirzepatide (Mounjaro): TA1026

NICE recommends tirzepatide for managing overweight and obesity only if an adult has:

BMI ≥ 35 kg/m², and
at least 1 weight-related comorbidity,
with a lower BMI threshold (usually reduced by 2.5) for specific ethnic groups.

NICE for semaglutide (Wegovy): TA875

NICE recommends semaglutide with criteria including:

BMI ≥ 35, or
BMI 30–34.9 if they meet criteria for referral to specialist services (per NICE obesity guideline), with commercial arrangement conditions.

Why this matters: On the NHS, “who qualifies” can differ between the two appraisals. In practice, local commissioning can also tighten criteria beyond NICE (so you may see variation by area).

4) NHS access reality (how it’s actually being implemented)

For tirzepatide, NHS England published interim commissioning guidance tied to NICE TA1026 and phased rollout considerations.

Why this matters: even if NICE recommends a treatment, NHS access can be staged via specialist services and local pathways.

5) Side effects & tolerance (what usually feels similar)

Both medicines are in the “appetite regulation injection” category and both commonly have gastrointestinal side effects (especially early during dose escalation). Their leaflets emphasise gradual titration/escalation.

What matters for you:

your past tolerance of similar medicines
your ability to follow escalation plans
your lifestyle setup (meal size, hydration, food choices), which can change side-effect severity

If you want the “why appetite changes happen,” read: How Mounjaro Works for Weight Loss.

Comparison table: differences that change decisions

Difference	Mounjaro	Wegovy	Why it matters
Active ingredient	Tirzepatide	Semaglutide	Different mechanism & dose structures
Dose range format	2.5-15mg pen strengths	Escalation to 2.4mg; option to 7.2mg via 3 injections	Injection “experience” differs
NICE NHS criteria	TA1026 BMI≥35 + comorbidity (plus ethnicity adjustment)	TA875 BMI≥35 or 30–34.9 with specialist referral criteria	Eligibility can differ on NHS
UK regulatory update	Authorised for weight management (strengths listed)	7.2mg approved Jan 2026 (3 injections)	Changes what “max dose” means in UK

“Which should I choose?” (non-prescriptive scenarios)

These are discussion starters for your clinician not self-prescribing rules:

If you care most about single-injection simplicity: Wegovy’s 7.2mg
If NHS eligibility is your main concern: NICE criteria differ between TA1026 (tirzepatide) and TA875 (semaglutide).
If you’re choosing via private consultation: your clinician will focus on safety, history, current medicines, BMI/measurements, and tolerance.

If you’re proceeding with Mounjaro via MedCare, start here:
Mounjaro weight loss injection pen.

FAQs

Is Mounjaro “stronger” than Wegovy?

They are different medicines with different mechanisms and dosing systems. The better choice depends on eligibility, tolerance, medical history, and clinician judgement not a one-line “stronger” claim.

Has Wegovy’s maximum dose changed in the UK?

Yes. The MHRA announced approval of a 7.2mg weekly Wegovy dose for some obesity patients, delivered as three 2.4mg injections on the same day.

Does NICE recommend both for obesity management?

Yes NICE has guidance for tirzepatide (TA1026) and semaglutide (TA875), each with its own criteria.